Techniques for increasing the yield of stem cell-derived exosomes: what factors may be involved?

Zi-Yuan Feng†, Qing-Yi Zhang†, Jie Tan & Hui-Qi Xie*

Laboratory of Stem Cell and Tissue Engineering, Orthopedic Research Institute, Med-X Center for Materials, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China

Received July 26, 2021; accepted August 11, 2021; published online October 9, 2021

Exosomes are nano-scale extracellular vesicles secreted by cells and constitute an important part in the cell-cell communication. The main contents of the exosomes include proteins, microRNAs, and lipids. The mechanism and safety of stem cell-derived exosomes have rendered them a promising therapeutic strategy for regenerative medicine. Nevertheless, limited yield has restrained full explication of their functions and clinical applications. To address this, various attempts have been made to explore the up- and down-stream manipulations in a bid to increase the production of exosomes. This review has recapitulated factors which may influence the yield of stem cell-derived exosomes, including selection and culture of stem cells, isolation and preservation of the exosomes, and development of artificial exosomes.

Introduction

Exosomes were discovered about 50 years ago, since then research to decipher their underlying mechanisms has been thriving (Anderson, 1969; Crawford, 1971). All cells can generate this type of extracellular vesicles (EVs) with an average diameter of 100 nm (usually in a range between 40 and 160 nm) and a cup shape under an electronic microscope (Mehryab et al., 2020). The exosomes comprise a myriad of bioactive compounds, including proteins, microRNAs, lipids, and DNA segments (Ferguson and Nguyen, 2016), which play a crucial role in the interplay of diverse cells (Kowal et al., 2014; Kalluri and LeBleu, 2020). The exosomes are generated and derived from a special bilayer organelle called multivesicular body (MVB). The formation of MVB includes several phases: (1) germination, starting with the formation of an incurvate structure at specific loci on the cell membrane; (2) formation of early-sorting endosomes (ESEs), which results in its outside-in plasma membrane orientation; (3) late-sorting endosomes (LSEs), which are matured from the ESEs when precursors of the exosomes, namely intraluminal vesicles (ILVs), are germinating, and (4) transformation to mature MVBs with ILVs lying at inside. Notably, as the formation of the exosomes is associated with specific sorting mechanisms, the compounds in such vesicles are divergent from other EVs, e.g., microvesicles, microparticles and other large vesicles, with respect to membrane proteins, lipids, and inclusions (Figure 1) (Trajkovic et al., 2008; Kowal et al., 2014; Kalluri and LeBleu, 2020). Such characteristics can also help with the discrimination of the exosomes from other vesicular structures.

Stem cell-based therapies have been tailored for the treatment of a broad range of diseases (Ratajczak et al., 2006; Bruno et al., 2019; Zakrzewski et al., 2019). Over 1,200 clinical trials involving utilization of mesenchymal stem
cells (MSCs) have so far been registered in ClinicalTrials.gov (Phinney and Pittenger, 2017). Inspiringly, apparent benefit and safety have been noted in most of these trials. Stem cell-derived exosomes possess favorable pharmacokinetic property, biocompatibility, and tissue-targeting ability owing to their bilayer structures and constituents of mRNAs, microRNAs, cytokines, chemokines, and immunomodulatory compounds (Mendt et al., 2019; Harrell et al., 2019; Haraszti et al., 2019; Fernández-Francos et al., 2021). Moreover, the ability of the exosomes to suppress inflammation, regulate cell proliferation, and promote damaged tissue repair has been corroborated (Harrell et al., 2019; Massa et al., 2020), for example, in the skin (An et al., 2021), muscle and bone (Nakamura et al., 2015; Hao et al., 2017; Mianehsaz et al., 2019), nerve (Tsintou et al., 2021), heart (Bahardoust and Baghoi-Hosseinabadi, 2021), liver (Zhao et al., 2020), kidney (Ishiy et al., 2020), lung (Xu et al., 2020), immune system (Burrello et al., 2016), cancer (Sharma, 2018), and virus infection (Jamshidi et al., 2021) (Figure 2). Introduction of the exosomes into biomaterials, such as exosome-laden hydrogel (Wang et al., 2019a; Wang et al., 2019b), exosome-coated scaffold (Zhai et al., 2020; Kyung Kim et al., 2021), and exosome-based drug delivering vectors (Barile and Vassalli, 2017; Mehryab et al., 2020), has

---

**Figure 1** Biogenesis and identification of exosomes. Exosomes originate from plasma membrane, and can be followed by fusion with the endoplasmic reticulum, trans-Golgi network, and mitochondria. The process goes through several stages and involves numerous pathways including Rab GTPases and ESCRT. The exosomes contain membrane and luminal constituents, including CD9, CD63, CD81, flotillin, TSG101, ceramide, and Alix, which can be used as molecular markers (Kalluri and LeBleu, 2020).
also become hot topics in regenerative medicine research. Compared with stem cell-based therapies, exosome-based therapies are more promising owing to their better delineated mechanisms. Moreover, the merits of resolution of the tumorigenicity, toxicity, and immune rejection associated with cell therapy, along with the convenience to obtain the exosomes without damages to the cells, have further expanded the design and clinical application of exosome-based therapies (Kuriyan et al., 2017; Mendt et al., 2019).

Nevertheless, the feasibility of exosome-based therapies is still limited, which may be attributed to the trivial amount of the exosomes by individual cells and lack of efficient extracting strategy (Colao et al., 2018; Kalluri and LeBleau, 2020). As discovered, a dose of 800 μg kg⁻¹ exosomes is required to render a notable clinic therapeutic effect (Lee et al., 2021). However, only about 10 μg exosomes can be harvested from 1 mL of 2D static stem cell culture medium by ultracentrifugation (Patel et al., 2019; Z. Wu et al., 2021), which suggested that there is still a long way to go before real clinical application. During the last decade, research devoted to enhancing the production of exosomes has increased. Strategies to improve the yield of exosomes have included up- and downstream manipulations (Lai et al., 2010; Colao et al., 2018). Upstream manipulations included selection of stem cells with high productivity (Haraszti et al., 2018), addition of soluble factors (Wang et al., 2020), modification of culture condition (Zhu et al., 2018), and application of high-density cell culture techniques (Kim et al., 2018). Downstream manipulations comprised development of a diverse range of separation methods including gradient centrifugation, precipitation of polymers, ultrafiltration, exclusion chromatography, immunoaffinity adsorption, and microfluidics (Li et al., 2017; D. Yang et al., 2020). As another downstream manipulation, storage conditions have also been improved to facilitate the exosome-based therapy (Charoenviriyakul et al., 2018). Furthermore, artificial exosomes have also been explored for producing exosomes with low cost, high output, and homogenous quality (García-Manrique et al., 2018). In this review, we have systematically summarized the strategies to increase the yield of stem cell-derived exosomes, with an aim to provide reference and inspiration for further research in this field.

Selection of stem cells

The generation and secretion of the exosomes are under complex regulation. Accordingly, the amount and properties of the exosomes are divergent due to their diverse origins, which may lead to discrepant therapeutic outcomes (Haraszti et al., 2016; Charoenviriyakul et al., 2017; Alvarez-Viejo, 2020). Therefore, rigorous selection of appropriate stem cells is crucial for enhancing the yield of the exosomes. MSCs, which are well defined by the International Society for Cell and Gene Therapy (Dominici et al., 2006), are the most widely used stem cells for exosome studies. The MSCs can be further classified into several subcategories based on their source of derivation including bone marrow, adipose tissue, umbilical cord, skin, dental pulp, and menstrual blood (Lopez-Verrilli et al., 2016; Alvarez-Viejo, 2020). Among these, bone marrow mesenchymal stem cells (BMSCs), adipose mesenchymal stem cells (ADSCs), and human umbilical mesenchymal stem cells (HUMSCs) are most widely studied. As mentioned above, the constituents and therapeutic efficacy of the exosomes derived from disparate stem cells are different (Table 1) (Lopez-Verrilli et al., 2016; Börger et al., 2017; Ji et al., 2019; Alvarez-Viejo, 2020). The divergent ability of exosome secretion by different stem cells may in part account for this phenomenon. As discovered, HUMSCs can secrete exosomes by approximately 4-fold in quantity compared with BMSCs and ADSCs, while concurrently with the largest size (Haraszti et al., 2018). Meanwhile, such exosomes are also stable when cultured in serum-free medium, which is advantageous for massive production (Haraszti et al., 2019).

Other types of stem cells have also been studied, though their secreting capacity and therapeutic efficacy have not been fully explored (Yuan et al., 2018). It would be valuable to obtain comparative data on exosomes from other stem cells such as the urine-derived stem cells (Chen et al., 2018), dental pulp stem cells (Faruqu et al., 2020), and other newly discovered stem cells.

Culture methods of stem cells

The yield of exosomes can be influenced by modification of the culturing condition of stem cells, which may include adjustment of culture medium components, environment parameters or even modes of cultivation. Such factors may in turn influence the properties of exosomes and alter the productivity of the stem cells by regulating their behaviors (Table 2).

Soluble factors

A feasible way to enhance the secretion of exosomes of stem cells is by addition of certain soluble cytokines directly into the culture medium. A myriad of bioactive cytokines, including lipopolysaccharide (LPS) (Ti et al., 2015), N-methyl-dopamine (Wang et al., 2020), noradrenaline (Wang et al., 2020), and adiponectin (Kita and Shimomura, 2020), have been tried. In such a context, the property and therapeutic efficacy of exosomes may also be changed. Of note, some Chinese medicine, e.g., Suxiao Jiuxin pills, has been shown to contain biomolecules that can elevate the magni-
tude of exosome secretion by stem cells (Ruan et al., 2018).

Unfortunately, even though the soluble factors have shown the validity in influencing the exosome secretion by stem cells, there is still a long way to go before large-scale applications due to certain limitations including potential physiological status alternation and internalization of the agents into the parent cells (Silva et al., 2015; Zou et al., 2019). Hence, researchers have been reluctant to add soluble factors.
factors for preserving the potential of the culture medium. In fact, the main purpose of adding soluble cytokines to the culture medium was to delineate the mechanisms by which the secretion of exosomes is regulated.

**Chemical/physical stimulation**

Cells may alter their characteristics to adapt to changes of their environment, and such alternations can be partially reflected by their secretions. As tissue generators, stem cells have been proven to be activated when tissue damage signals are triggered. Based on this rationale, researchers are inspired to create the damage-mimetic micro-environment chemically or physically during stem cell cultivation, with an aim to obtain exosomes with boosted production and therapeutic functions (Pusic et al., 2016; Yin et al., 2019).

| Soluble factors | Cellular origin | Fold increase | Characteristic alternation | Reference |
|----------------|----------------|---------------|---------------------------|-----------|
| N-methyldopamine and nor-epinephrine | BMSCs | 3-fold | No significant alternation in the structure, composition and therapeutic effect of exosomes | Wang et al., 2020 |
| LPS | HUMSCs | 1.37-fold | Let-7b was upregulated, which enhanced Immunotherapeutic effect | Ti et al., 2015 |
| Adiponectin | Endothelial F2T cells | 3-fold | Adiponectin was present in exosomes | Obata et al., 2018 |
| Suxiao Jiuxin pills | Cardiac MSCs | 3-fold | Rab27a, SYTL4, Rab27b proteins and the small GTPases were upregulated | Ruan et al., 2018 |
| Chemical/physical stimulation | | | | |
| Serum-deprived stress | BMSCs, ADSCs, HUMSCs | No significant improvement | Exosome activity was improved, while MVs activity was impaired | Haraszti et al., 2019 |
| Hypoxia stress | BMSCs, ADSCs, | – | Therapeutic molecular including miRNA (miR-216a-5p, miR-125b, etc.) and proteins are upregulated | ZHU et al., 2018; LIU et al., 2020; GELTNER et al., 2021 |
| Flow or stretch stimulation | Dental MSCs, ADSCs, skeletal muscle cells | Up to 40.7-fold, differ between the cells | Isolated EVs showed typical structure, whereas 216 proteins were differentially expressed | Guo et al., 2021 |
| Mechanical stimulation caused by a rotary cell culture system | HUMSCs | 4-fold | Exosome composition, especially IncRNA H19, was upregulated, which enhanced the therapeutic effect | L. Yan et al., 2021 |
| High frequency acoustic irradiation stimulating | U87-MGcells | 8–10-fold | The EVs size distribution of stimulated cells consisted primarily of exosomes | Ambattu et al., 2020 |
| 3D Culture | | | | |
| 3D spheroid culture | BMSCs | 2–3-fold, decreased with increasing 3D spheroid size | Not mentioned | Kim et al., 2018 |
| 3D-printed scaffold-perfusion bioreactor system | Human dermal microvascular endothelial cells | 10,000-fold by NTA, 14-fold by CD63 ExoELISA and 6.5-fold by BCA | Total protein content per exosome showed significant decrease | Patel et al., 2019 |
| Engineered 3D tissue and flow bioreactor | Dental MSCs, ADSCs, skeletal muscle cells | Up to 40.7-fold (differ between the cells) | Isolated EVs showed typical structure, whereas 216 proteins were differentially expressed | Guo et al., 2021 |
| Microcarrier-based 3D culture | HUMSCs | 20-fold | Proteomics analysis showed 357 high-abundance proteins detected in all exosome variants and 21–369 low-abundance proteins unique to an exosome variant | Haraszti et al., 2018 |
| Biomaterials | | | | |
| Nitric oxide-releasing polymer | Human placenta-derived MSCs | No significant improvement | MiR-126 was upregulated, which enhanced the pro-angiogenic activity of exosomes | Du et al., 2017 |
| Li-incorporated bioactive glass ceramic | BMSCs | No significant improvement | MiR-130a was upregulated, which enhanced the pro-angiogenic activity of exosomes | Liu et al., 2019 |
| PLGA nanoparticle | BMSCs | 2-fold | Specific antioxidants or tissue regeneration factors may be increased | Park et al., 2020 |
| Bioglass | BMSCs | 2-fold | The ability of promoting ECs vascularization was enhanced | Z. Wu et al., 2021 |
from the MSCs treated with hypoxia usually exhibited an enhanced therapeutic effect (Zhu et al., 2018; Liu et al., 2020; Geßner et al., 2021). Serum deprivation was another novel means to stimulate the secretion of exosomes by the stem cells, as substances in the culture serum may also to some extent interfere with the secretion (J. Li et al., 2015; Haraszti et al., 2019). In addition, mechanical forces such as flow and stretching factors have also been shown to impact the secretion of exosomes (J.Li et al., 2015; Haraszti et al., 2019). Serum deprivation was another novel means to stimulate the secretion of exosomes by the stem cells, as substances in the culture serum may also to some extent interfere with the secretion (J. Li et al., 2015; Haraszti et al., 2019). In addition, mechanical forces such as flow and stretching factors have also been shown to impact the secretion of exosomes (J.Li et al., 2015; Haraszti et al., 2019). Serum deprivation was another novel means to stimulate the secretion of exosomes by the stem cells, as substances in the culture serum may also to some extent interfere with the secretion (J. Li et al., 2015; Haraszti et al., 2019). In addition, mechanical forces such as flow and stretching factors have also been shown to impact the secretion of exosomes (J.Li et al., 2015; Haraszti et al., 2019).

3D culture

Along with the development of upstream manipulation techniques, researchers have tried 3D culture for enhancing the yield of exosomes. The 3D culture can maximize the culturing area and incessantly apply a shear force (Colao et al., 2018). An early method was the hanging-drop in a 3D spheroid culture (Kim et al., 2018). However, the efficiency of this method was stagnated after a gain by only 2–3-fold. Patel et al. increased the yield of exosomes by nearly 100-fold by culturing the cells on a 3D printed hollow fibrillar scaffold with a complementary perfusion system (Patel et al., 2019). However, subsequent experiments have found that the morphology and component of exosomes were significantly altered. The membrane proteins were critically decreased through such a process. Worse still, the fabrication procedure of this 3D-printing scaffold was too complex to be widely adapted.

Microcarrier-based suspension culture is so far the most suitable platform for 3D stem cell cultivation and has been extensively used for commercialized production (Tavassoli et al., 2018; Koh et al., 2020). The method was firstly applied in 2015 for the extraction of the exosomes (Jarmalavičiūtė et al., 2015). Researchers noted that, compared with the other two types of MSCs (BMSCs and ADSCs), HUMSCs derived from Wharton’s jelly had the highest yield of exosomes, and the output could be further increased by approximately 20-fold when a microcarrier suspension culture system was applied, or even 140-fold when a tangential flow filtration system was introduced (Haraszti et al., 2018). This work was subsequently adapted by Xu et al. for the development of an exosome-based therapy (Ling et al., 2020). Furthermore, a bioreactor system invented by Tsinghua University has proven to be convenient for large-scale production of stem cell-derived exosomes (Yan et al., 2020). Nevertheless, the culturing parameter and shear stress during suspension cultivation should be carefully evaluated in order to limit cell death and phenotype transformation (Becquart et al., 2016).

Biomaterials

The materials of culture substrate may provide another avenue for increasing the yield of stem cell-derived exosomes. Typical examples include NO-releasing polymer (Du et al., 2017), lithium-incorporated bioactive glass ceramic (Liu et al., 2019), ferroferric oxide coated PLGA nanoparticles (Park et al., 2020) and bioglass (Z. Wu et al., 2021). In addition to the productivity, biomaterials could also improve the therapeutic efficacy of exosomes by forming a specific micro-environment to interact with the cells, which may to some extent determine the fate of stem cells (Novoseletskaia et al., 2019). Although many biomaterials have been demonstrated to influence the paracrine of stem cells (Peng et al., 2017), definite validations regarding the exosomes are scarce. Nevertheless, biomaterials and cultivation technologies could be combined, for instance, by extracellular matrix (ECM)-derived microcarriers, to further enhance the secretion of exosomes by stem cells (Turner and Flynn, 2012; Kornmuller et al., 2017).

Isolation of exosomes

In addition to the aforementioned upstream manipulations, isolation techniques are also critical to increase the yield of exosomes. Currently available techniques for the extraction of exosomes are mainly based on their chemical, physical, and immunological properties, and are adapted from the methods used for the extraction of virus and microvesicles, such as ultracentrifugation, polymer precipitation, ultrafiltration, exclusion chromatography, immunoaffinity chromatography, and microfluidics. To date, technology and facility designed exclusively for the extraction of exosomes are scarce (Li et al., 2017; Lane et al., 2017; D. Yang et al., 2020). Similar to upstream manipulations, the selection of extracting methods may impact not only the yield of exosomes, but also their characteristics such as size, structure, and biofunction (Rekker et al., 2014) (Table 3). Hence, isolation methods should be carefully selected based on the aim of research as well as characteristics of the method and sample. Notably, with proper combination, up- and downstream manipulations could be integrated in a multiplicative manner to increase the total yield of exosomes substantially.

Centrifugation and sedimentation

Differential ultracentrifugation, or ultracentrifugation, has
remained the standard method for extracting exosomes. The rationale behind this technique is that cell fragments, apoptotic bodies, and other large-size components in the culture medium can be separated according to their respective volume, density, and morphology (Witwer et al., 2013; Zarovni et al., 2015). Despite that ultracentrifugation has a high productivity and is easy to use, its clinical translation is limited due to low specificity, time-consuming, requirement of expensive device, difficulty in extracting exosomes from small-sized sample, and the causally occurred fusion of the extracted exosomes.

Density-gradient centrifugation can overcome the drawback of lacking specificity in ultracentrifugation by a special density-gradient medium method, which can be further classified into two categories, i.e., the isopycnic and moving-zone density-gradient centrifugation (D. Yang et al., 2020; Li et al., 2017). For isopycnic density-gradient centrifugation, the medium (usually comprised of sucrose and iodixanol) was set in a tapered density gradient from the bottom to the top. By this way, the dissolved substances with similar density will stay in a same layer, thus separating the exosomes from other compounds with large density discrepancy (Greening et al., 2015; D. Yang et al., 2020). Nevertheless, it is still difficult to separate the EVs with similar densities, resulting in impurity of exosomes.

In order to isolate the exosomes from other compounds with similar densities such as MVs, a moving-zone density-gradient centrifugation technique was developed, where a centrifugal medium with a density lower than other solvents was used. All dissolved substances in the system are incessantly moving during centrifugation (Li et al., 2017; D. Yang et al., 2020). Therefore, by carefully calculating the parameters of the exosomes and other compounds (such as MVs) and setting the centrifugation time, the exosomes could be isolated according to their disparate size, mass as well as density (D. Yang et al., 2020). Even though such procedures are sophisticated, tedious, and with limited handling capacity compared with the ultracentrifugation method, it has the advantages of high specificity, broad application, and higher output, which have rendered it a suitable alternative for extracting special exosomes from media with limited sample availability, e.g., plasma and other biofluids (Greening et al., 2015).

Of note, polymer precipitation has been reported to efficiently increase the sedimentation rate of exosomes, which could decrease the centrifugal force required for extracting exosomes. The polymers can absorb the water on the surface of exosomes, making them easier to precipitate even at a lower centrifugation speed, thus producing exosomes with simpler equipment in less time. Furthermore, low cost and convenience to manipulate are also merits of polymer precipitation (Zeringer et al., 2015). Unfortunately, soluble proteins may also be precipitated during this process, thus affecting the purity of extracted exosomes (Lane et al., 2017). To this end, researchers are endeavored to improve the sample capacity of polymer precipitation, for instance, by introduction of PEG (Börger et al., 2020) and protamine (Deregibus et al., 2016). Currently, the majority of commercially available extracting kits, such as ExoQuick and Total Exosomes Isolation, are adapted from such methods (Ryu et al., 2020).

### Size-based technique

For the tiny size of the exosomes, it is feasible to separate them from proteins and other large EVs. Ultrafiltration is a method for extracting the exosomes by their difference in size (Zeringer et al., 2015; Cardoso et al., 2021). As reported, ultrafiltration technique not only can filter out small-size compounds to obtain relatively pure exosomes, but also has the advantages of rapidity, stability, automation, and higher recovery, which may further expand its application in the

| Isolation technique | Principle, Surface marker expression, size, density, etc. | Sample volume | Process time | Purity | Recovery | Reference |
|---------------------|----------------------------------------------------------|----------------|--------------|--------|----------|-----------|
| Differential         | Sedimentation rate                                       | 100s of mL     | 3–6 h        | Low    | 5%–20%   | Tauro et al., 2012; Nordin et al., 2015 |
| Gradient ultracentrifugation | Density, size and shape                               | ~1 mL         | 20–24 h      | High   | 10%–40%  | Tauro et al., 2012 |
| Polymer precipitation | Sedimentation rate                                       | >100 μL        | 2–18 h       | Low    | 5%–30%   | Ye Tang et al., 2017; Börger et al., 2020 |
| Ultrafiltration      | Size                                                     | ~10 mL         | 1–3 h        | Moderate | ~30%     | Nordin et al., 2015 |
| Tangential flow filtration | Size                                                      | 100s of mL     | 1–2 h        | Moderate | ~80%     | Basatto et al., 2018 |
| Size-exclusion chromatography | Size                                                      | ~1 mL         | 1–2 h        | Moderate | 40%–80%  | Gámez-Valero et al., 2016; Moleirinho et al., 2019 |
| Immunoaffinity capture | Surface marker expression                               | ~100 μL        | 18–20 h      | Very high | >90%    | Foroni et al., 2020 |
| Microfluidics-based techniques | Surface marker expression, size, density, etc.          | ~100 μL        | 1–3 h        | High    | 40%–90%  | Liu et al., 2017; Han et al., 2021 |

---

**Table 3** Exosome isolation techniques

Feng, Z.Y., et al. *Sci China Life Sci* July (2022) Vol.65 No.7
future (Heinemann et al., 2014). However, EVs with a larger size may rupture owing to the powerful stress during filtration, which may release other inclusions to contaminate the exosomes. Meanwhile, blockade and rupture of the filter membrane are often inevitable (Battrakova and Kim, 2015).

As a result, tangential flow filtration (TFF) strategy, a method originally used for extracting viruses and proteins, was adapted to prevent the filtrated particles from damage, possibly by allowing the dissolved substances to tangentially filtrate through the membrane. During the TFF, samples can be re-circulated to repeat the process several times to improve the recovery of exosomes (Haraszti et al., 2018; Busatto et al., 2018; Han et al., 2021). Given the advantage of high sample capacity and automation, and the ability to isolate exosomes with high purity, it is possible to produce stem cell-derived exosomes on an industrial scale by using TFF.

Exclusion chromatography technology has also been tested for it can gently isolate the exosomes without ultracentrifugation (Lai et al., 2010; Cardoso et al., 2021). Despite the low recovery, the purity of exosomes obtained in this way is comparable to that by density gradient ultracentrifugation, while structure disruption caused by the centrifugal force may be avoided (Lobb et al., 2015). Nevertheless, it is difficult for such method to separate the exosomes from other vesicles or particles with similar diameters such as MVs and protein polymers.

**Immune-based technique**

Accurate identification of the copious surface markers such as CD9, CD63, CD81, and phosphoryl serine (Kosaka et al., 2013; Montecalvo et al., 2013) is critical for the development of specific antibodies and receptors to bind with such protein markers to capture the exosomes. As reported, exosomes extracted from 450 μL medium by immunoaffinity was equal to the amount extracted from 2.5 mL medium by ultracentrifugation (Zarovni et al., 2015; Y. Tang et al., 2017). Apart from immunoaffinity column chromatography, magnetic pellets with immobilized antibodies have also been widely utilized for the separation and validation of the exosomes (Clayton et al., 2001; McBride et al., 2017). Immunoaffinity methods may suit exosome research perfectly by generating a high purity product with a good recovery rate. On the other hand, drawbacks such as high cost and sophisticated manipulation have limited its application on a larger scale (Foroni et al., 2020). To further improve the efficiency of extracting exosomes by immunoaffinity extraction, a method based on immunoassay upon mass spectrometry has been developed (Ueda et al., 2014).

**Microfluidics**

Among the newly developed strategies for extracting and analyzing the exosomes, microfluidics has been the mostly studied and adapted. By this means, the extracting device can precisely isolate the exosomes based on their physical and chemical properties. Other isolation strategies, such as tangential flow filtration (Han et al., 2021), can be integrated with the microfluidic chip and greatly improve the efficiency and specificity of exosome extraction, in particular for small-sized samples (Liu et al., 2017; Contreras-Naranjo et al., 2017).

The strategies of microfluidics used for the extraction of exosomes have included not only the surface antigen, density and size recognition, but also elastic lift force (Liu et al., 2017), ultrasonic waves (Lee et al., 2015), and electrophoretic manipulations (Ayala-Mar et al., 2019), whilst the dissociation strategies can be classified into contact type and non-contact type (D. Yang et al., 2020). Based on such technology, multilayer micro-nano fluid technology was developed to further improve the efficiency of exosome extraction (Sundaram et al., 2020). Due to its low sample handling capacity, microfluidic technologies have often been applied to analyze exosomes from small-sized samples. Nevertheless, integration of exosome manipulations with highly automated mode is still worthy to explore.

**Others**

For the resemblance between the viruses and macro-molecules in exosomes, technologies used for the extraction of viruses have been used for the extraction of exosomes. These included flow field-flow fractionation (Kang et al., 2008; Zhang and Lyden, 2019), static water filtration dialysis (Musante et al., 2014), etc. As mentioned above, a PEG precipitation technique, originally used for virus extraction, has demonstrated a high efficiency to extract exosomes from several liters of culture medium at a time (Börger et al., 2020). Furthermore, considering the similarity between exosomes and other nanoparticles, it is feasible to extract exosomes in any laboratory equipped with facilities for the extraction of proteins and viruses.

To overcome the shortcoming of individual method, combined techniques have been tested. For instance, the isopycnic gradient ultracentrifugation and ultrafiltration can be combined, for which the isopycnic gradient ultracentrifugation is efficient to separate particles with different densities, while the ultrafiltration can subsequently purify the exosomes according to their size. Zhang et al. (2021) have developed a method called immunomagnetic sequential ultrafiltration, which consists of a tangential flow filtration step and a magnetic-bead antibody-based EV capture step. The combination of ultrafiltration and size-exclusion chromatography is also a novel strategy worthy of consideration (Nordin et al., 2015; Cardoso et al., 2021).
Storage of exosomes

Storage of exosomes also bears a great deal of importance. Without eligible storage technology, long-term storage cannot be achieved. In this circumstance, exosomes have to be produced whenever a demand emerges, which can severely increase the burden to the packaging, transportation, and preparation. Therefore, it is necessary to develop a method to store the exosomes in a relatively gentle condition with easy access.

Ambient temperature and time are recognized as the most crucial elements affecting the viability and quantity of the exosomes stored, as bioactive proteins in the exosomes will gradually degrade with the increase of temperature and storage time (Oosthuyzen et al., 2013; Welch et al., 2017; Jeyaram and Jay, 2017; Qin et al., 2020). By contrast, membrane proteins, DNA and RNA in the exosomes seem to be insignificantly affected by the storage temperature (Zonneveld et al., 2014; Ge et al., 2014; Sarkar et al., 2014; Jin et al., 2016). As discovered, -80°C is the optimal temperature for the storage of exosomes, at which the loss of bioactive proteins and exosomes can be efficiently suppressed (Jeyaram and Jay, 2017). However, the properties of exosomes will still degrade to some extent during the storage (Maroto et al., 2017). Wu et al. have systemically explored the change of the property of the exosomes stored at various temperatures, and found -80°C to be the optimum temperature for the long-term storage (J. Wu et al., 2021).

To enhance the stability of exosomes, certain additives were introduced into the stock solution. For instance, addition of certain protease inhibitors into the storage solution has proven to be beneficial to protect the compounds in exosomes from degradation (Oosthuyzen et al., 2013). Furthermore, combination of thawing (Zhou et al., 2006) with certain preservative agents such as DMSO, sucrose, and mycose (Tegegn et al., 2016) are also helpful for improving the recycle rate of the exosomes. Researchers even proposed an assessment system to evaluate the degradation of the EVs stored under various conditions, which has provided a precious reference for research in this field (Richter et al., 2019).

Although exosomes have shown a fare stability when stored at ~80°C, this temperature may be unrealistic in most factories during the fabrication and transportation of exosomes. A more convenient and efficient storage condition is therefore required. Lyophilization, which is commonly used for the preservation of bioactive compounds, has been adopted for the storage of exosomes (El-Nesr et al., 2010). Although this method has carried a risk of disrupting the membrane of exosomes, it still represents an optimum solution for the storage of the exosomes when protective agents are introduced (Bahr et al., 2020). Moreover, as discovered, the exosomes could be stored for more than a week at room temperature with minimal loss in quantity and bioactive compounds with the introduction of cryoprotectant mycose (Charoenviviyakul et al., 2018). The efficacy of such technique was found to be similar to that with storage at ~80°C. Furthermore, spray drying, a method often used for preparation and storage of unstable drugs, may also be considered for the storage of exosomes (Bahr et al., 2020).

Artificial exosomes

As aforementioned, exosomes are bioactive compounds with complex components and can act as nanoscale tools for cell communication. Such characteristics have conferred them with excellent targeting ability and biocompatibility (van der Meel et al., 2014; Yáñez-Mó et al., 2015; Surman et al., 2019). As discovered, a diversity of membrane proteins, e.g., CD47, a marker highly expressed by cancer cells for evading the immunophagocytosis, is the main contributor to the therapeutic effect of exosomes (Kamerkar et al., 2017). Incorporation of gold particles on exosome membranes can confer them with an ability to escape immunophagocytosis (Van Deun et al., 2020). Accordingly, by producing stem cell-derived exosomes artificially, the steps and/or the time taken by the stem cells to secrete exosomes may be saved, thereby increasing the yield of exosomes. To produce more homogenous exosomes on a large scale, artificial exosomes have been considered as biomolecules as they are relatively clear and can be controlled to some extent (Figure 3).

Genetic engineering

Gene-editing technique represents as a novel and powerful means for modifying the exosomes derived from stem cells (Li et al., 2018). Researchers have improved the therapeutic outcome of certain diseases by over-expressing bioactive compounds such as miR-181-5p (Qu et al., 2017), miR-214 (Shi et al., 2021), and miR-155-5p (Damasceno et al., 2020) in the MSCs. Sterzenbach et al. have fabricated a drug vector to penetrate the blood-brain barrier by modifying the ESCRT-associated genes (Sterzenbach et al., 2017). To make the stem cell-derived exosomes as an optimal drug carrier, importation of some unmodified bioactive compounds (such as miRNAs) directly into the isolated exosomes by CaCl2 or electroporation has also been explored (Zhang et al., 2017; Liu and Su, 2019).

Although gene-modified strategy has substantially advanced our understanding of the secretion and synthesis of exosomes, the exploration to increase the yield of exosome by such techniques is still in its infancy (Kowal et al., 2014; Kalluri and LeBleu, 2020). Various pathways, e.g., the ESCRT protein and Rab GTPase, have been found to play a critical role in the synthesis and secretion of exosomes (Katzmann et al., 2001; Ostrowski et al., 2010; Li et al.,
Recently, researchers have also made an endeavor to upregulate the expression of genes associated with exosome secretion, including the ESCRT-III-Associated Protein Alix (Ji et al., 2021), HIF-1, and mTORC1 (Zou et al., 2019). Meanwhile, study of the culture condition has also identified other pathways such as Rab GTPase (Ruan et al., 2018; Z. Wu et al., 2021) and YAP (Guo et al., 2021) associated with exosome releasing. Such findings could be leveraged in combination to produce stem cells with an exosome-productive genotype, in this way the application of exosomes may be extensively expanded. However, certain compounds, such as ceramide (Dreux et al., 2012) and cholesterol (Strauss et al., 2010), not only are correlated with exosome synthesis, but also have influences on other intracellular metabolic activities. For this reason, the consequences elicited by gene-editing are still hard to predict. More importantly, exosomes and virus share certain similarities in multiple layers, thus the risk of contaminating the exosomes with undesirable virus genes is inevitable (Colao et al., 2018). Such shortcomings should be overcome prior to application of such techniques for massive exosome yielding.

**Cell fragmentation**

Fragmentation of the cells into nanovesicles with a size equal to that of exosomes has also turned out to be a promising strategy (García-Manrique et al., 2018). Copious membrane proteins and special lipids are typical features of exosomes (Haraszi et al., 2019). All membrane proteins and lipids of the source cells could be utilized for the manufacture of exosomes (Goh et al., 2017). Accordingly, microfluidics can squeeze the cells into a hydrophilic channel to fragment them into exosome-analogous nanovesicles, by which abundant miRNA and surface proteins may be produced (Jo et al., 2014). Furthermore, cutting the cells with silicon nitride blades during their passage through the microfluidic channels can generate a more homogenous batch of exosomes (Yoon et al., 2015). Such cells can be further fragmented to
nanovesicles by replacing the blade with centrifugation or electricity to force them to cross a nano-membrane (Jo et al., 2014; Lee et al., 2020). Other chemical methods such as radioimmunoprecipitation analysis have also been used to produce nanovesicles with a size similar to that of exosomes (Martinelli et al., 2020). Notably, combination of the aforementioned techniques with gene expression modifications, such as miRNA overexpression, has also been tested (Z. Yang et al., 2020).

**Exosome mimetic liposome**

The methods for fabricating artificial exosomes are diverse. Liposome, an artificially-made vesicle composed of lipid and cholesterol, possesses sound biocompatibility and drug loading capacity. However, clinical applications of liposomes are scarce due to their undesirable immunogenicity and unsatisfactory stability, biocompatibility, targeting ability, and absorbability (Antimisiaris et al., 2018; Guimarães et al., 2021). Such drawbacks can be largely overcome by fabricating an exosome-liposome complex, by which the advantages of two can complement each other (Haraszti et al., 2019; Sakai-Kato et al., 2020). In theory, artificial exosomes with their laden nucleic acid antigen can be employed to target dendritic cells by the self-assembly of microemulsion micelle. In such artificial exosomes, lecithin, cholesterol, dioleoylphosphatidyl-lethanolamine (DOPE), DC-Chol, and NBD-PE are leveraged to fabricate the lipid membranes, while the monoclonal antibody DEC205 and fetal bovine serum (BSA) are used to fabricate the surface proteins (K. Li et al., 2015). Furthermore, a pulsed jet method has also been developed to produce nanovesicles with lipid compositions analogous to those of exosomes (Kamiya et al., 2021). Although chemical synthesis of exosomes is still in its infancy, their prospect for the management of intractable diseases such as autoimmunity and tumors has already attracted much attention (Schiffelers et al., 2012; Vázquez-Ríos et al., 2019). Meanwhile, particular moieties of the naturally derived exosomes have also been used as raw material to synthesize artificial exosomes and to study their underlying mechanisms (Haraszti et al., 2019).

**Semi-artificial exosome**

Semi-artificial exosomes may also be used for improving the function and yield of stem cell-derived exosomes. By fusing extracellular vesicles with drug-laden liposomes (by co-incubating with PEG or without), researchers have successfully fabricated a hybrid exosome with outstanding cargo capacity, absorbability, and targeting ability, which may ultimately yield better therapeutic outcomes (Piffoux et al., 2018; Lin et al., 2018). The biocompatibility and targeting

---

**Figure 4** Methods that can maximize the yield of exosomes, in which the cell sources, culture manipulations, and isolation techniques can be adopted to increase the yield of exosomes.
This work has been sponsored by the National Natural Science Foundation of China (31771065), Sichuan Science and Technology Program (2019JDRC0020), and the “1.3.5 Program for Disciplines of Excellence,” West China Hospital, Sichuan University (ZYJC18002).

References
Alvarez-Viejo, M. (2020). Mesenchymal stem cells from different sources and their derived exosomes: A pre-clinical perspective. World J Stem Cells 12, 100–109.
Ambat, L.A., Ramesan, S., Dekiwadia, C., Hanssen, E., Li, H., and Yeo, I.Y. (2020). High frequency acoustic cell stimulation promotes exosome generation regulated by a calcium-dependent mechanism. Commun Biol 3, 553.
An, Y., Lin, S., Tan, X., Zhu, S., Nie, F., Zhen, Y., Gu, L., Zhang, C., Wang, B., Wei, W., et al. (2021). Exosomes from adipose-derived stem cells and application to skin wound healing. Cell Prolif 54, e12993.
Anderson, H.C. (1969). Vesicles associated with calcification in the matrix of epithysseal cartilage. J Cell Biol 41, 59–72.
Antimisiaris, S.G., Mourtas, S., and Marazioti, A. (2018). Exosomes and exosome-inspired vesicles for targeted drug delivery. Pharmaceuticals 10, 218.
Ayal-Mar, S., Gallo-Villanueva, R.C., and González-Valdez, J. (2019). Dielectrophoretic manipulation of exosomes in a multi-section microfluidic device. Mater Today-Proc 13, 332–340.
Bahardoust, M., and Baghoi-Hosseinabadi, Z. (2021). ROLE of adipose-derived mesenchymal stem cells in the regeneration of cardiac tissue and improvement of cardiac function: a narrative review. Biointerface Res Appl Chem 11, 8446–8456.
Bahr, M.M., Amer, M.S., Abo-El-Sououd, K., Abdallah, A.N., and El-Tookhy, O.S. (2020). Preservation techniques of stem cells extracellular vesicles: a gate for manufacturing of clinical grade therapeutic extracellular vesicles and long-term clinical trials. Int J Vet Sci Med 8, 1–8.
Barile, L., and Vassalli, G. (2017). Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol Ther 174, 63–78.
Batrakova, E.V., and Kim, M.S. (2015). Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release 219, 396–405.
Becquart, P., Cruel, M., Hoc, T., Sudre, L., Pernelle, K., Bizios, R., Logeart-Avramoglou, D., Petite, H., and Bensidhoum, M. (2016). Human mesenchymal stem cell responses to hydrostatic pressure and shear stress. Eur Cell Mater 31, 160–173.
Bergese, P., and Wolfram, J. (2018). Tangential flow filtration for highly efficient concentration of extracellular vesicles from large volumes of plasma. J Control Release 269, 218.
Börger, V., Bremer, M., Ferrer-Tur, R., Gockeln, L., Stambouli, O., Becic, A., and Giebel, B. (2017). Mesenchymal stem/stromal cell-derived extracellular vesicles and their potential as novel immunomodulatory therapeutic agents. Int J Mol Sci 18, 1450.
Börger, V., Staubach, S., Dittrich, R., Stambouli, O., and Giebel, B. (2020). Scaled isolation of mesenchymal stem/stromal cell-derived extracellular vesicles. Curr Prot Stem Cell Biol 55, e128.
Bruno, S., Chiabotto, G., Favaro, E., Deregibus, M.C., and Camussi, G. (2019). Role of extracellular vesicles in stem cell biology. Am J Physiol-Cell Physiol 317, C303–C313.
Burrello, J., Levent, S., Gai, C., Gomez, Y., Kholia, S., and Camussi, G. (2016). Stem cell-derived extracellular vesicles and immune-modulation. Front Cell Dev Biol 4, 83.
Busatto, S., Vilanilam, G., Ticer, T., Lin, W.L., Dickson, D.W., Shapiro, S., Bergese, P., and Wolfram, J. (2018). Tangential flow filtration for highly efficient concentration of extracellular vesicles from large volumes of fluid. Cells 7, 273.
Cardoso, R.M.S., Rodrigues, S.C., Gomes, C.F., Duarte, F.V., Romao, M., Leal, E.C., Freire, P.C., Neves, R., and Simões-Correia, J. (2021). Development of an optimized and scalable method for isolation of umbilical cord blood-derived small extracellular vesicles for future clinical use. Stem Cells Transl Med 10, 910–921.
Charoenviriyakul, C., Takahashi, Y., Morishita, M., Matsumoto, A., Nishikawa, M., and Takakura, Y. (2017). Cell type-specific and common characteristics of exosomes derived from mouse cell lines: Yield, physicochemical properties, and pharmacokinetics. Eur J Pharm...
Chiari, M.V., Ratnayake, R., Buda, J., et al. (2021). Impact of mesenchymal stem cell-derived exosomes on treatment of kidney damage induced by chronic renal artery stenosis. J Am Soc Nephrol 32, 2940–2951.

Clavijo, P., de la Garza, A., Haridas, S., et al. (2018). Exosomes as a potential diagnostic tool for disease management. J Cell Physiol 233, 2347–2358.

Cobo, J.M., Gómez-Caballero, C., Llorente, J.M., et al. (2017). Mesenchymal stem cells: a promising tool for regenerative medicine. Cell Mol Life Sci 74, 1621–1647.

Cortez, D., Oliveira, P.F., Prata, A., and Veríssimo, R. (2018). Exosome-based approaches for the diagnosis of cancer: evidence and challenges. Cell Mol Life Sci 75, 4195–4208.

Covell, J., Joly, K., and Zaman, R. (2016). Exosomes as therapeutic candidates for hyperproliferative diseases. J Cell Physiol 231, 4119–4128.

Cordero, G.M., Solís, V., and Martín, E. (2020). Exosomes in metagenomics: a new perspective in the identification of microorganisms. Front Microbiol 11, 370.

Cordero-García, J., Zúñiga, A., and Gómez-Carmenate, F. (2017). Exosomes in cancer: a promising tool for personalized medicine. J Cell Mol Med 21, 199–212.

Costa, L.A., Escudero-Cernuda, S., Faruqui, F.N., Zhou, S., Sami, N., Gheidari, F., Lu, H., and Al-Jamal, K.T. (2010). Effect of Du, W., Zhang, K., Zhang, S., Wang, R., Nie, Y., Tao, H., Han, Z., Liang, N., Bhatnagar, D., and Puissant, A. (2019). Exosomes: a promising therapeutic platform. Trends Mol Med 24, 242–256.

Contreras-Naranjo, J.C., Wu, H.J., and Ugaz, V.M. (2017). Microfluidics for exosome isolation and analysis: enabling liquid biopsy for personalized medicine. Lab Chip 17, 3558–3577.

Crowford, N. (1971). The presence of contractile proteins in platelet microparticles isolated from human and animal platelet-free plasma. Br J Haematol 21, 53–69.

Damasceno, P.K.F., de Santana, T.A., Santos, G.C., Orge, I.D., Silva, D.N., Albuquerque, J.F., Golimelli, G., Grisendi, G., Pinelli, M., Ribeiro Dos Santos, R., et al. (2020). Genetic engineering as a strategy to improve the therapeutic efficacy of mesenchymal stromal/stem cells in regenerative medicine. Front Cell Dev Biol 8, 737.

Dereugb, M.C., Figioliini, F., D’Antico, S., Manzini, P.M., Pasquino, C., De Lena, M., Tetta, C., Brizzi, M.F., and Camussi, G. (2016). Charge-based precipitation of extracellular vesicles. Int J Mol Med 38, 1359–1366.

Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marin, F.C., Krause, D.S., Deans, R.J., Keating, A., Prockop, D.J., and Horwitz, E.M. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315–317.

Druez, M., Garagorta, U., Boyd, B., Décembre, E., Chung, J., Whitten-Bauer, C., Wieland, S., and Chisari, F.V. (2012). Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. Cell Host Microbe 12, 558–570.

Du, W., Zhang, K., Zhang, S., Wang, R., Nie, Y., Tao, H., Han, Z., Wang, D., Liu, J., et al. (2017). Enhanced proangiogenic potential of mesenchymal stem cell-derived exosomes stimulated by a nitric oxide releasing polymer. Biomaterials 133, 70–81.

El-Nesr, O.H., Yahiya, S.A., and El-Gazayerly, O.N. (2010). Effect of Exosome isolation and analysis: enabling liquid biopsy for personalized medicine. Lab Chip 17, 3558–3577.

Feng, Z.Y., et al. Sci China Life Sci July (2022) Vol.65 No.7 1337
Kornmuller, A., Brown, C.F.C., Yu, C., and Flynn, L.E. (2017). Fabrication
Kita, S., and Shimomura, I. (2020). Stimulation of exosome biogenesis by
Koh, B., Sulaiman, N., Fauzi, M.B., Law, J.X., Ng, M.H., Idrus, R.B.H.,
Kim, M., Yun, H.W., Choi, B.H., and Min, B.H. (2018). Three-
Kuriyan, A.E., Albini, T.A., Townsend, J.H., Rodriguez, M., Pandya, H.K.,
Kowal, J., Tkach, M., and Théry, C. (2014). Biogenesis and secretion of
Kosaka, N., Yoshioka, Y., Hagiwara, K., Tominaga, N., and Ochiya, T.
Kang, D., Oh, S., Lee, B.H., and Moon, M.H. (2008). Proteomic
Lane, R.E., Korbie, D., Trau, M., and Hill, M.M. (2017). Purification
Ji, L., Bao, L., Gu, Z., Zhou, Q., Liang, Y., Zheng, Y., Xu, Y., Zhang, X.,
Feng, (2019). Comparison of immunomodulatory properties of exosomes
derived from bone marrow mesenchymal stem cells and dental pulp stem cells. Immunol Res 67, 432–442.
Ye, J., Han, W., Fu, X., Li, J., Wu, Q., and Wang, Y. (2021). Improved small
extracellular vesicle secretion of rat adipose-derived stem cells by
microglowed substrates through upregulation of the ESCRT-III-associated protein alix. Adv Healthcare Mater 10, 2100492.
Jin, Y., Chen, K., Wang, Z., Wang, Y., Liu, J., Lin, L., Shao, Y., Gao, L.,
Yin, H., Cui, C., et al. (2016). DNA in serum extracellular vesicles is stable under different storage conditions. BMC Cancer 16, 753.
Jo, W., Jeong, D., Kim, J., Cho, S., Jiang, S.C., Han, C., Kang, J.Y., Gho, Y. S.,
and Park, J. (2014). Microfluidic fabrication of cell-derived nanovesicles as endogenous RNA carriers. Lab Chip 14, 1261–1269.
Jo, W., Kim, J., Yoon, J., Jeong, D., Cho, S., Jeong, H., Yoon, Y.J., Kim, S. C.,
Gho, Y.S., and Park, J. (2014). Large-scale generation of cell-derived nanovesicles. Nanoscale 6, 12056–12064.
Kalluri, R., and LeBleu, V.S. (2020). The biology, function, and biomedical applications of exosomes. Science 367, eaau6977.
Kamersk, S., LeBleu, V.S., Sagimoto, H., Yang, S., Ruivo, C.F., Melo, S. A.,
Lee, J.J., and Kalluri, R. (2017). Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546, 498–503.
Kamiya, K., Osaki, T., and Takeuchi, S. (2021). Formation of nano-sized lipid vesicles with asymmetric lipid components using a pulsed-jet flow method. Sens Actuat B-Chem 327, 128917.
Kang, D., Oh, S., Ahn, S.M., Lee, B.H., and Moon, M.H. (2008). Proteomic analysis of exosomes from human neural stem cells by flow field-flow fractionation and nanoflow liquid chromatography–tandem mass spectrometry. J Proteome Res 7, 3475–3480.
Katzmann, D.J., Babst, M., and Err, S.D. (2001). Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I. Cell 106, 145–155.
Kim, M., Yun, H.W., Park, D.Y., Choi, B.H., and Min, B.H. (2018). Three-dimensional spheroid culture increases exosome secretion from mesenchymal stem cells. Tissue Eng Regen Med 15, 427–436.
Kita, S., and Shimomura, I. (2020). Stimulation of exosome biogenesis by adiponectin, a circulating factor secreted from adipocytes. J Biochem 169, 173–179.
Koh, B., Sulaiman, N., Fauzi, M.B., Law, J.X., Ng, M.H., Idrus, R.B.H., and Yazid, M.D. (2020). Three dimensional microcarrier system in mesenchymal stem cell culture: a systematic review. Cell Bioici 10, 75.
Kornmuller, A., Brown, C.F.C., Yu, C., and Flynn, L.E. (2017). Fabrication of Extracellular Matrix-derived Foams and Microcarriers as Tissue-specific Cell Culture and Delivery Platforms. J Vis Exp, ,doi: 10.3791/ 55436.
Kosaka, N., Yoshioka, Y., Hagiwara, K., Tominaga, N., and Ochiya, T. (2013). Functional analysis of exosomal microRNA in cell-cell communication research. Methods Mol Biol 1024, 1–10.
Koval, J., Tkach, M., and Théry, C. (2014). Biogenesis and secretion of exosomes. Curr Opin Cell Biol 29, 116–125.
Kuriyan, A.E., Albini, T.A., Townsend, J.H., Rodriguez, M., Pandya, H.K.,
Leonard Li, R.E., Parrott, M.B., Rosenfeld, P.J., Flynn Jr., H.W., and
Goldberg, J.L. (2017). Vision loss after intravitreal injection of monoclonal antibody coupled cationic nanoliposomes for simulating exosomes to target dendritic cells. Int J Pharm 491, 105–112.
Li, D., Aslan, B., Lee, J.J., and Kalluri, R. (2017). Exosomes facilitate therapeutic delivery of synthetic drugs and gene therapy payloads to tumors. Chin J Cancer Res 29, 476–488.
Li, K., Chang, S., Wang, Z., Zhao, X., and Chen, D. (2015). A novel microfluidic device for exosome isolation techniques. Theranostics 7, 789–804.
Li, S.P., Lin, Z.X., Jiang, X.Y., and Yu, X.Y. (2018). Exosomal cargo-loading and synthetic exosome-mimics as potential therapeutic tools. Acta Pharmacol Sin 39, 542–551.
Lin, Y., Wu, J., Gu, W., Huang, Y., Tong, Z., Huang, L., and Tan, J. (2018). Exosomes-liposome hybrid nanoparticles deliver CRISPR/Cas9 system in MSCs. Adv Sci 5, 1700611.
Ling, Y., Xu, W., Yang, L., Liang, C., and Xu, B. (2020). Improved the biocompatibility of cancellous bone with compound physicochemical decellularization process. Regen Biomater 7, 443–451.
Liu, C., Guo, J., Tian, F., Yang, N., Yan, F., Ding, Y., Wei, J.Y., Hu, G., Nie, G., and Sun, J. (2017). Field-free isolation of exosomes from extracellular vesicles by microfluidic viscoelastic flows. ACS Nano 11, 6968–6976.
Liu, C., and Su, C. (2019). Design strategies and application progress of therapeutic exosomes. Theranostics 9, 1015–1028.
Liu, L., Liu, Y., Feng, C., Chang, J., Fu, R., Wu, T., Yu, F., Wang, X., Xia, L., Wu, C., et al. (2019). Lithium-containing biomaterials stimulate bone marrow stromal cell-derived exosomal miR-130a secretion to promote angiogenesis. Biomaterials 192, 523–536.
Liu, W., Rong, Y., Wang, J., Zhou, Z., Ge, X., Ji, C., Jiang, D., Gong, F., Li, L., Chen, J., et al. (2020). Exosome-shuttled miR-216a-5p from hypoxic preconditioned mesenchymal stem cells repair traumatic spinal cord injury by shifting microglial M1/M2 polarization. J Neuroinflamm 17, 47.
Lobb, R.J., Becker, M., Wen Wen, S., Wong, C.S.F., Wiegmans, A.P., Leimgruber, A., and Möller, A. (2015). Optimized exosome isolation protocol for cell culture supernatant and human plasma. J Extracell Vesicles 4, 27031.
Lopez-Verrilli, M.A., Caviedes, A., Cabrera, A., Sandovall, S., Wyneken, U., and Khoury, M. (2016). Mesenchymal cell derived exosomes from different sources selectively promote neutritic outgrowth. Neuroscience 320, 129–139.
Luo, L., Tang, J., Nishi, K., Yan, C., Dinh, P.U., Cores, J., Kudo, T., Zhang, J., Li, T.S., and Cheng, K. (2017). Fabrication of synthetic mesenchymal stem cells for the treatment of acute myocardial infarction in mice. Circ Res 120, 1768–1775.
Maroto, R., Zhao, Y., Jamaluddin, M., Popov, V.V., Wang, H.,
Kalubowilage, M., Zhang, Y., Luisi, J., Sun, H., Culbertson, C.T., et al. (2017). Effects of storage temperature on airway exosome integrity for diagnostic and functional analyses. J Extracell Vesicles 6, 1359478.
Martinelli, C., Gabriele, F., Dini, E., Carriero, F., Bresciani, G., Slivinschi, B., Dei Giudici, M., Zanoletti, L., Manai, F., et al. (2020). Development of artificial plasma membranes derived nanovesicles suitable for drugs encapsulation. Cells 9, 1626.
Massa, M., Croce, S., Camparelli, R., Abbà, C., Lenta, E., Valsecchi, C.,
and Avanzini, M.A. (2020). Clinical applications of mesenchymal stem/stromal cell derived extracellular vesicles: therapeutic potential of an
acellular product. *Diagnoses* 10, 999.

McBride, J.D., Rodriguez-Mencos, L., Guzman, W., Candanedo, A., Garcia-Contreras, M., and Badiu, E.V. (2017). Bone marrow mesenchymal stem cell-derived CD63+ exosomes transport Wnt3a extracellularly and enhance dermal fibroblast proliferation, migration, and angiogenesis *in vitro*. *Stem Cells Dev* 26, 1384–1398.

Mehraby, R., Fabbani, S., Shahhosseini, S., Shekari, F., Fatahi, Y., Baharvand, H., and Haeri, A. (2020). Exosomes as a next-generation drug delivery system: An update on drug loading approaches, characterization, and clinical application challenges. *Acta Biomater* 113, 42–62.

Mendt, M., Rezvani, K., and Shpall, E. (2019). Mesenchymal stem cell-derived exosomes for clinical use. *Bone Marrow Transplant* 54, 789–792.

Miachelsz, E., Mirzaei, H.R., Mahjoubin-Tehran, M., Rezaee, A., Sahnebasagh, R., Pourhani, F.H., Mirzaei, H., and Hamblin, M.R. (2019). Mesenchymal stem cell-derived exosomes: a new therapeutic approach to osteoarthritis? *Stem Cell Res Ther* 10, 340.

Moleirinho, M.G., Silva, R.J.S., Carrondo, M.J.T., Alves, P.M., and Peixoto, C. (2019). Exosome-based therapeutics: Purification using semi-continuous multi-column chromatography. *Sep Purif Technol* 224, 515–523.

Montecalvo, A., Larregina, A.T., and Morelli, A.E. (2013). Methods of analysis of dendritic cell-derived exosome-shuttle microRNA and its horizontal propagation between dendritic cells. *Methods Mol Biol* 1024, 19–40.

Musante, L., Tataruch, D., Gu, D., Benito-Martin, A., Calzaferi, G., AHERNE, S., and Holthofer, H. (2014). A simplified method to recover urinary vesicles for clinical applications and sample banking. *Sci Rep* 4, 7532.

Nakamura, Y., Miyaki, S., Ishitobi, H., Matsuyama, S., Nakasa, T., Kamei, N., Akimoto, T., Higashi, Y., and Ochi, M. (2015). Mesenchymal-stem-cell-derived exosomes accelerate skeletal muscle regeneration. *FEBS Lett* 589, 1257–1265.

Nordin, J.Z., Lee, Y., Vader, P., Mäger, I., Johansson, H.J., Heusermann, W., Wiklander, O.P.B., Hallbrink, M., Seow, Y., Bulema, J.J., et al. (2015). Ultrafiltration with size-exclusion liquid chromatography for high yield isolation of extracellular vesicles preserving intact biophysical and functional properties. *NanoMed-Nanotechnol Biol Med* 11, 879–883.

Novoseletskaya, E.S., Grigorieva, O.A., Efimenko, A.Y., and Kalinina, N.I. (2019). Exocellular matrix in the regulation of stem cell differentiation. *Biochem Moscow* 84, 232–240.

Obata, Y., Kitay, S., Koyama, Y., Fukuda, S., Takeda, H., Takahashi, M., Fujishima, Y., Nagao, H., Masuda, S., Tanaka, Y., et al. (2018). Adiponectin/T-cadherin system enhances exosome biogenesis and decreases cellular ceramics by exosomal release. *JCI Insight* 3, e99680.

Oosthuizen, W., Sime, N.E.L., Ivy, J.R., Tortle, E.J., Street, J.M., Pound, J., Bath, L.E., Webb, D.J., Gregory, C.D., Bailey, M.A., et al. (2013). Quantification of human urinary exosomes by nanoparticle tracking analysis. *J Physiol* 591, 5833–5842.

Ostrowski, M., Carro, N.B., Krumeich, S., Fanget, J., Raposo, G., Savina, A., Moita, C.F., Schauer, K., Hume, A.N., Freitas, R.P., et al. (2010). Rab27a and Rab27b control different steps of the exosome secretion pathway. *Nat Cell Biol* 12, 19–30.

Park, D.J., Yun, W.S., Kim, W.C., Park, J.E., Lee, S.H., Ha, S., Choi, J.S., Key, J., and Seo, Y.J. (2020). Improvement of stem cell-derived exosome release efficiency by surface-modified nanoparticles. *J Nanobiotechnol* 18, 178.

Patel, D.B., Luthers, C.R., Lerman, M.J., Fisher, J.P., and Jay, S.M. (2019). Enhanced extracellular vesicle production and ethanol-mediated vascularization bioactivity via a 3D-printed scaffold-perfusion bioreactor system. *Acta Biomater* 95, 236–244.

Peng, K.Y., Liu, Y.H., Li, W.Y., Yen, B.L., and Yen, M.L. (2017). Extracellular matrix protein laminin enhances mesenchymal stem cell (MSC) paracrine function through αvβ3/CD61 integrin to reduce cardiomycocyte apoptosis. *J Cell Mol Med* 21, 1572–1583.

Phinney, D.G., and Pittenger, M.F. (2017). Concise review: MSC-derived exosomes for cell-free therapy. *Stem Cells* 35, 851–858.

Piffkous, M., Silva, A.K.A., Wilhelm, C., Gazeau, F., and Tareste, D. (2018). Modification of extracellular vesicles by fusion with liposomes for the design of personalized biogenic drug delivery systems. *ACS Nano* 12, 6830–6842.

Pusic, K.M., Pusic, A.D., and Kraig, R.P. (2016). Environmental enrichment stimulates immune cell secretion of exosomes that promote CNS myelination and may regulate inflammation. *Cell Mol Neurobiol* 36, 313–325.

Qin, B., Zhang, Q., Hu, X.M., Mi, T.Y., Yu, H.Y., Liu, S.S., Zhang, T., Tang, M., Huang, J.F., and Xiong, K. (2020). How does temperature play a role in the storage of extracellular vesicles? *J Cell Physiol* 235, 7663–7680.

Qu, Y., Zhang, Q., Cai, X., Li, F., Ma, Z., Xu, M., and Lu, L. (2017). Exosomes derived from miR-181-5p-modified adipose-derived mesenchymal stem cells prevent liver fibrosis via autophagy activation. *J Cell Mol Med* 21, 2491–2502.

Ratajczak, J., Mickus, K., Kucia, M., Zhang, J., Reca, R., Dvorak, P., and Ratajczak, M.Z. (2006). Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. *Leukemia* 20, 847–856.

Rekker, K., Saare, M., Roost, A.M., Kubo, A.L., Zarovni, N., Chiesi, A., Salumets, A., and Peters, M. (2014). Comparison of serum exosome isolation methods for miRNA profiling. *Clin Biochem* 47, 135–138.

Richter, M., Fuhrmann, K., and Fuhrmann, G. (2019). Evaluation of the storage stability of extracellular vesicles. *J Vis Exp*, doi: 10.3791/59854.

Ruan, X.F., Ju, C.W., Shen, Y., Liu, Y.T., Kim, I.M., Yu, H., Weintraub, N., Wang, X.L., and Tang, Y. (2018). Suxiajiuxin pill promotes exosome secretion from mouse cardiac mesenchymal stem cells *in vitro*. *Acta Pharmacol Sin* 39, 569–578.

Ryu, K.J., Lee, J.Y., Park, C., Cho, D., and Kim, S.J. (2020). Isolation of small extracellular vesicles from human serum using a combination of ultracentrifugation and polymer-based precipitation. *Ann Lab Med* 40, 253–258.

Sakai-Kato, K., Yoshida, K., Takechi Haraya, Y., and Izutsu, K.I. (2020). Physicochemical characterization of liposomes that mimic the lipid composition of exosomes for effective intracellular trafficking. *Langmuir* 36, 12735–12744.

Sarker, S., Scholz-Romer, K., Perez, A., Illanes, S.E., Mitchell, M.D., Rice, G.E., and Salomon, C. (2014). Placenta-derived exosomes continuously increase in maternal circulation over the first trimester of pregnancy. *J Transl Med* 12, 204.

Schifflers, R., Koojims, S., Vander, S., van Dommelen, S., and Van Solinge, S. (2012). Exosome mimetics: a novel class of drug delivery systems. *Int J Nanomed* 7, 1525–1541.

Sharma, A. (2018). Role of stem cell derived exosomes in tumor biology. *Int J Cancer* 142, 1086–1092.

Shi, J., Jiang, X., Gao, S., Zhu, Y., Liu, J., Gu, T., and Shi, E. (2021). Gene-modified exosomes protect the brain against prolonged deep hypothermic circulatory arrest. *Ann Thoracic Surg* 111, 576–585.

Silva, A.K.A., Luciani, N., Gazeau, F., Aubertin, K., Bonneau, S., Chauviere, C., Letourneau, D., and Wilhelm, C. (2015). Combining magnetic nanoparticles with cell derived microvesicles for drug loading and targeting. *NanoMed-Nanotechnol Biol Med* 11, 645–655.

Sterzenbach, U., Putz, U., Low, L.H., Silke, J., Tan, S.S., and Howitt, J. (2017). Engineered exosomes as vehicles for biologically active proteins. *Mol Ther* 25, 1269–1278.

Stauss, K., Goebel, C., Runz, H., Möbius, W., Weiss, S., Feussner, I., Simons, M., and Schneider, A. (2010). Exosome secretion ameliorates lysosomal storage of cholesterol in Niemann-Pick type C disease. *J Biol Chem* 285, 26279–26288.

Sundaram, P.M., Casadei, L., Lopez, G., Braggio, D., Balakirsky, G., Pollock, R., and Prakash, S. (2020). Multi-layer micro-nanofluidic device for isolation and capture of extracellular vesicles derived from...
87, 46–58.

Zeringer, E., Barta, T., Li, M., and Vlassov, A.V. (2015). Strategies for isolation of exosomes. Cold Spring Harb Protoc 2015(4), pdb.top074476.

Zhai, M., Zhu, Y., Yang, M., and Mao, C. (2020). Human mesenchymal stem cell derived exosomes enhance cell-free bone regeneration by altering their miRNAs profiles. Adv Sci 7, 2001334.

Zhang, D., Lee, H., Zhu, Z., Minhas, J.K., and Jin, Y. (2017). Enrichment of selective miRNAs in exosomes and delivery of exosomal miRNAs in vitro and in vivo. Am J Physiol-Lung Cell Mol Physiol 312, L110–L121.

Zhang, H., and Lyden, D. (2019). Asymmetric-flow field-flow fractionation technology for exomere and small extracellular vesicle separation and characterization. Nat Protoc 14, 1027–1053.

Zhang, J., Nguyen, L.T.H., Hickey, R., Walters, N., Wang, X., Kwak, K.J., Lee, L.J., Palmer, A.F., and Reátegui, E. (2021). Immunomagnetic sequential ultrafiltration (iSUF) platform for enrichment and purification of extracellular vesicles from biofluids. Sci Rep 11, 8034.

Zhao, L., Wang, Y., and Zhang, Y. (2020). The potential diagnostic and therapeutic applications of exosomes in drug-induced liver injury. Toxicol Lett 337, 68–77.

Zhou, H., Yuen, P.S.T., Pisitkun, T., Gonzales, P.A., Yasuda, H., Dear, J.W., Gross, P., Knepper, M.A., and Star, R.A. (2006). Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery. Kidney Int 69, 1471–1476.

Zhu, L.P., Tian, T., Wang, J.Y., He, J.N., Chen, T., Pan, M., Xu, L., Zhang, H.X., Qiu, X.T., Li, C.C., et al. (2018). Hypoxia-elicited mesenchymal stem cell-derived exosomes facilitates cardiac repair through miR-125b-mediated prevention of cell death in myocardial infarction. Theranostics 8, 6163–6177.

Zonneveld, M.I., Brisson, A.R., van Herwijnen, M.J.C., Tan, S., van de Lest, C.H.A., Redegeld, F.A., Garssen, J., Wauben, M.H.M., and Nolte-′t Hoen, E.N.M. (2014). Recovery of extracellular vesicles from human breast milk is influenced by sample collection and vesicle isolation procedures. J Extracell Vesicles 3, 24215.

Zou, W., Lai, M., Zhang, Y., Zheng, L., Xing, Z., Li, T., Zou, Z., Song, Q., Zhao, X., Xia, L., et al. (2019). Exosome release is regulated by mTORC1. Adv Sci 6, 1801313.